Anteris Technologies Global Corp. (AVR) Price & Analysis

Compare

41 Followers

AVR Stock Chart & Stats

$5.93

-$0.12(-2.09%)

At close: Jan 08 4:00 PM EST

$5.93

-$0.12(-2.09%)

Day’s Range― - ―

52-Week Range$2.34 - $8.79

Previous Close$5.88

Volume157.53K

Average Volume (3M)180.35K

Market Cap

$152.02M

Enterprise Value$110.67M

Total Cash (Recent Filing)$9.12M

Total Debt (Recent Filing)$2.35M

Price to Earnings (P/E)―

Beta1.97

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.12

Shares Outstanding41,197,570

10 Day Avg. Volume148,268

30 Day Avg. Volume180,351

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.80

Price to Sales (P/S)41.81

P/FCF Ratio-1.78

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue51.74

Enterprise Value/Gross Profit76.15

Enterprise Value/Ebitda-1.31

Forecast

1Y Price Target

$17.50

Price Target Upside195.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.24

Revenue Forecast (FY)$2.67M

Bulls Say, Bears Say

Bulls Say

Clinical Development ProgressWith the clinical trial design accepted in the US and enrollment commencement already in play OUS, Anteris is positioned to make significant strides in the DurAVR clinical development program and move down the US and OUS regulatory pathways.

Clinical Trial ResultsNew data from the DurAVR Small Aortic Annuli Pooled Cohort demonstrated stellar one-year hemodynamic outcomes as well as safety and efficacy results.

Regulatory ApprovalAnteris announced that the FDA issued IDE approval for the PARADIGM PMA trial, which will allow the company to move toward initiation of enrollment in the US.

Bears Say

Anteris Technologies Global Corp. News

Anteris Technologies receives FDA approval to initiate PARADIGM trial

Anteris announced it has received U.S. Food and Drug Administration, FDA, approval to initiate PARADIGM, its global Investigational...

14d ago

AVR

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

Anteris Technologies (AVR) Global announced one-year clinical outcomes for the DurAVR Transcatheter Heart Valve, or THV, in symptomatic...

19d ago

AVR

Anteris Technologies treats first patient in DurAVR heart valve pivotal trial

Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart...

20d ago

AVR

Anteris Technologies to present on one-year outcomes for DurAVR THV

Anteris Technologies (AVR) announced that one-year clinical outcomes with the DurAVR Transcatheter Heart Valve will be presented by...

21d ago

AVR

Anteris Technologies: Strategic Advancements and FDA Approval Bolster Buy Rating

Anteris Technologies Global Corp., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh...

13d ago

AVR

Anteris Technologies Receives FDA Approval for PARADIGM Trial

An announcement from Anteris Technologies Global Corp. ( ($AVR) ) is now available. On November 3, 2025, Anteris...

14d ago

AVR

Promising Investment Opportunity: Anteris Technologies’ DurAVR Platform Showcases Outstanding Clinical Outcomes

TD Cowen analyst Josh Jennings maintained a Buy rating on Anteris Technologies Global Corp. today and set a...

18d ago

AVR

Anteris Technologies Begins Global PARADIGM Trial Enrollment

The latest update is out from Anteris Technologies Global Corp. ( ($AVR) ). On October 27, 2025, Anteris...

20d ago

AVR

Anteris Technologies Raises $11.5M in Stock Offering

Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On October 23, 2025, Anteris Technologies Global...

20d ago

AVR

Anteris Technologies Announces Share Sale Agreement

Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On October 23, 2025, Anteris Technologies Global...

23d ago

AVR

Anteris Technologies Prepares for Annual Stockholder Meeting

Anteris Technologies Global Corp. ( ($AVR) ) has issued an announcement. Anteris Technologies Global Corp. will hold its...

1M ago

AVR

Anteris Technologies Gains European Clearance for Heart Valve Trial

The latest update is out from Anteris Technologies Global Corp. ( ($AVR) ). On October 15, 2025, Anteris...

1M ago

AVR

Anteris receives first European regulatory clearance to commence DurAVR trial

Anteris Technologies (AVR) announced it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR...

1M ago

AVR

Anteris Technologies Approves ASX Waiver Proposal

The latest announcement is out from Anteris Technologies Global Corp. ( ($AVR) ). On September 29, 2025, Anteris...

2M ago

AVR

AVR FAQ

What was Anteris Technologies Global Corp.’s price range in the past 12 months?

Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $8.79 in the past 12 months.

What is Anteris Technologies Global Corp.’s market cap?

Anteris Technologies Global Corp.’s market cap is $152.02M.

When is Anteris Technologies Global Corp.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Anteris Technologies Global Corp.’s earnings last quarter?

Anteris Technologies Global Corp. released its earnings results on May 13, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.491 by -$0.119.

Is Anteris Technologies Global Corp. overvalued?

According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anteris Technologies Global Corp. pay dividends?

Anteris Technologies Global Corp. does not currently pay dividends.

What is Anteris Technologies Global Corp.’s EPS estimate?

Anteris Technologies Global Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Anteris Technologies Global Corp. have?

Anteris Technologies Global Corp. has 41,197,570 shares outstanding.

What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?

Anteris Technologies Global Corp. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.491. Following the earnings report the stock price went up 6%.

Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?

Currently, no hedge funds are holding shares in AVR

Anteris Technologies Global Corp. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-2462.70%

Trailing 12-Months

Asset Growth

-9.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anteris Technologies Global Corp.

Anteris Technologies Global Corp. (AVR) is a biotechnology company focused on developing innovative solutions for cardiovascular disease. The company specializes in the research, development, and commercialization of advanced medical technologies, particularly in the area of heart valve replacements and repair. Anteris leverages its proprietary technologies to create products that aim to improve patient outcomes and enhance the quality of life for individuals suffering from heart conditions.

Anteris Technologies Global Corp. (AVR) Earnings & Revenues

Historic Earnings Reports

AVR Stock 12 Month Forecast

Average Price Target

$17.50

▲(195.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.683076923076923,6.876153846153846,8.06923076923077,9.262307692307694,10.455384615384617,11.64846153846154,12.841538461538462,14.034615384615385,15.227692307692308,16.42076923076923,17.613846153846154,18.806923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.4907692307692315,6.491538461538462,7.492307692307692,8.493076923076924,9.493846153846155,10.494615384615386,11.495384615384616,12.496153846153847,13.496923076923078,14.49769230769231,15.49846153846154,16.49923076923077,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.298461538461539,6.106923076923077,6.915384615384616,7.723846153846154,8.532307692307693,9.340769230769231,10.149230769230769,10.957692307692309,11.766153846153847,12.574615384615385,13.383076923076922,14.191538461538462,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.58,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >